A Phase 4 interventional study of DEFINITY® in Cardiovascular Disease, sponsored by Lantheus Medical Imaging. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-24.
Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this registry study is to gather safety information on the current clinical use of and the safety of DEFINITY®
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 1,060 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Lantheus Medical Imaging is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography
Drug: DEFINITY®
DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
Also known as: DEFINITY, Perflutren Lipid Microsphere injectable suspension
The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration
Time frame: during or within 30 minutes of administration
Serious Adverse Events
Summary of the number and percentage of participants with serious adverse events occuring following completion of DEFINITY administration
Time frame: Through 24 hours
Adverse Events
Summary of the number and percentage of participants with adverse events occuring following completion of DEFINITY administration
Time frame: Through 24 hours
Participants were recruited from hospitals and clinics in the USA between February 2008 and April 2009
| Milestone | DEFINITY® |
|---|---|
| Started | 1060 |
| Completed | 1053 |
| Not completed | 7 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: No iv access | 5 |
| Withdrew: Vsd | 1 |
| Participants | DEFINITY® |
|---|---|
| The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration | 0 |
Summary of the number and percentage of participants with serious adverse events occuring following completion of DEFINITY administration
| Participants | DEFINITY® |
|---|---|
| Serious Adverse Events | 0 |
Summary of the number and percentage of participants with adverse events occuring following completion of DEFINITY administration
| Participants | DEFINITY® |
|---|---|
| Adverse Events | 114 |
Collected over Through 24 hours post last dose. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DEFINITY® | — | 0/1,053 (0%) | 35/1,053 (3.3%) |
| Event | DEFINITY® |
|---|---|
| HeadacheNervous system disorders | 13/1053 |
| NauseaGastrointestinal disorders | 9/1053 |
| Back PainMusculoskeletal and connective tissue disorders | 7/1053 |
| TremorNervous system disorders | 6/1053 |
| Age, Categorical(Participants) | DEFINITY (Perflutren Lipid Microsphere) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 609 |
| >=65 years | 444 |
| Age, Continuous(years) | DEFINITY (Perflutren Lipid Microsphere) |
|---|---|
| Mean | 61.3 ± 12.9 |
| Sex: Female, Male(Participants) | DEFINITY (Perflutren Lipid Microsphere) |
|---|---|
| Female | 400 |
| Male | 653 |
The record gives a start of Feb 2008, a primary completion of May 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perflutren